表紙
市場調查報告書

煙酰胺磷酸核糖基轉移酶:開發中產品分析

Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 379069
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
煙酰胺磷酸核糖基轉移酶:開發中產品分析 Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 61 Pages
簡介

本報告提供以煙酰胺磷酸核糖基轉移酶為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

煙酰胺磷酸核糖基轉移酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Angelini Group
  • Aurigene Discovery Technologies Limited
  • Calico LLC
  • FORMA Therapeutics, Inc.
  • Genentech, Inc.
  • Karyopharm Therapeutics, Inc.
  • OncoTartis, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2039TDB

Summary

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Depression, Multiple Myeloma (Kahler Disease), Parkinson's Disease, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Respiratory Distress Syndrome, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammation, Leukemia, Lung Cancer, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Nerve Injury, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral T-Cell Lymphomas (PTCL), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sarcomas, Solid Tumor and Triple-Negative Breast Cancer (TNBC).

The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2019, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
  • The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Angelini Group
  • Aqualung Therapeutics Corp
  • Aurigene Discovery Technologies Ltd
  • Calico LLC
  • Eli Lilly and Co
  • Genentech Inc
  • Karyopharm Therapeutics Inc
  • OncoTartis Inc
  • Tianjin Hemay Pharmaceutical Co Ltd
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles
  • AU-4869 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Inhibit NAMPT for Inflammation and Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • enamptcumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GNE-617 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hemay-088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KPT-9274 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LSN-3154567 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OT-82 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • P7-C3A20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STF-118804 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products
  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference
  • Aug 20, 2019: Aqualung Therapeutics receives $225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome
  • Jun 05, 2019: Aqualung Therapeutics receives a $1.7 Million National Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury
  • Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting
  • Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting
  • Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
  • Aug 01, 2016: Pharmatek, a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies
  • Jun 27, 2016: OncoTartis: Initiated OT-82 GLP Toxicology and Safety Pharmacology studies
  • Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
  • Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting
  • Mar 15, 2016: OncoTartis Provides Update on OT-82
  • Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015
  • Mar 30, 2015: Oncotartis in collaboration with scientists from the Children's Cancer Institute of Australia for Medical Research initiated testing of OT-82
  • Oct 30, 2014: OncoTartis Provides Update on Toxicology study of OT-82
  • May 16, 2014: Nanosyn, a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AbbVie Inc, H2 2019
  • Pipeline by Angelini Group, H2 2019
  • Pipeline by Aqualung Therapeutics Corp, H2 2019
  • Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
  • Pipeline by Calico LLC, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Genentech Inc, H2 2019
  • Pipeline by Karyopharm Therapeutics Inc, H2 2019
  • Pipeline by OncoTartis Inc, H2 2019
  • Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top